- Home
- CAI
as 09-22-2025 2:30pm EST
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | IRVING |
| Market Cap: | 9.4B | IPO Year: | 2025 |
| Target Price: | $35.50 | AVG Volume (30 days): | 557.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -18.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.40 - $42.50 | Next Earning Date: | 11-12-2025 |
| Revenue: | $533,847,000 | Revenue Growth: | 106.53% |
| Revenue Growth (this year): | 64.66% | Revenue Growth (next year): | 45.81% |
Latest Caris Life Sciences Inc. Common Stock News
CAI Breaking Stock News: Dive into CAI Ticker-Specific Updates for Smart Investing
Insider Monkey
11 days ago
Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test
Zacks
11 days ago
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Compare CAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CAI Caris Life Sciences Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.